SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is actively trending following its mixed earnings report, where an EPS beat and strong growth in non-crypto segments like options, subscriptions, and prediction markets are being weighed against a revenue miss driven by a significant decline in crypto transaction revenue. The community is sharply divided on whether the stock's post-earnings dip is an overreaction to the crypto drag or indicative of deeper concerns, despite the company's diversification efforts and record net deposits.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending after reporting better-than-expected quarterly results and robust long-term growth targets, sparking bullish enthusiasm for its AI-driven lending model while also generating community frustration over the stock's immediate, muted price action despite the positive news.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

LYFT is trending after its earnings report, where a significant GAAP EPS beat was largely attributed to a non-recurring tax benefit, overshadowing overall bookings growth and a substantial $1 billion stock buyback program, leading to a sell-off and active community debate over its true valuation and future guidance.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending after exceeding recent earnings expectations and securing a major warrant deal with Amazon for future purchases. The community is actively debating its valuation amidst characteristic volatility, while acknowledging its crucial position in rapidly expanding AI infrastructure connectivity.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending ahead of its earnings release, where a significant EV restructuring charge and outlook for 2026, especially regarding its hybrid strategy, are key discussion points. The community is split between optimism for Ford's pivot and analyst upgrades, and concerns over recent recalls and the broader challenges facing the auto sector.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare (NET) is trending after reporting strong revenue and optimistic guidance that highlight its position in AI infrastructure, particularly with the Moltbot/Clawdbot buzz, although some investors are concerned about an EPS guidance miss and recent network outages.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel is trending due to a significant miss on its recent quarterly earnings and a cautious outlook, which led to a sharp stock decline that has investors debating whether it's an overreaction or a sign of deeper concerns for the toy giant.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to a significant stock drop following the termination of a $150 million funding agreement with a prospective tenant for its Project Matador data center campus. Despite the setback, the community is actively debating whether this presents a buying opportunity, highlighting the company's unique position to provide critical behind-the-meter power for the booming AI infrastructure demand in Texas amid ongoing tenant negotiations.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as its solid Q4 performance and increased dividend are contrasted by a conservative 2026 earnings outlook, sparking community discussion on whether this presents a buying opportunity amid perceived near-term weakness.

MNTN, Inc. engages in bringing performance marketing to television, ushering in a new generation of advertisers to Connected TV (CTV). The software company’s self-serve advertising platform and AI-driven precision targeting enable brands of all sizes to achieve measurable results. The company was founded by Mark Douglas in 2009 and is headquartered in Austin, TX.

MNTN Inc. - Ordinary Shares - Class A

MNTN, Inc.

MNTN is trending after a strong earnings report showcasing impressive revenue growth and profitability in its Performance TV platform, with analysts issuing multiple upgrades and bullish price targets. Despite the positive financial results, the stock experienced a significant pullback, prompting community discussion about whether it's an undervalued "buy the dip" opportunity or if ongoing patent lawsuits are contributing to the perplexing sell-off.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABCL Why consider buying ABCL?  Thanks to their AI, this company is able to identify a drug faster than almost anyone.  During COVID they discovered Bamlanivimab for Eli Lilly in just 11 days.  They screened 5 million cells and identified 500 unique sequence.  The drug went from discovery to human clinical trials in just 3 months and was approved by the FDA in 8 months.  Such process usually takes 5-10 years. 
 
They use credit card chips to screen millions of B cells.  Their AI predicts which sequence is most developable to prevent failure during manufacturing.   
 
They have full backing of the Canadian government with several grants totaling about $295 million.  They have almost $1.3 billion in total assets and are debt free.  They started developing their own drugs and within 6 months we will hear something about their most important trial ABCL365 to help with hot flashes caused by menopause (VMS market) is estimated at $17 billion/yr and will grow to $21 billion by 2030.

Stonk Trades

Debbie Whitaker

Fractal

Luis De La Ossa

Tyler

$ABCL &quot;Faster than anybody else&quot;, Bro it&#39;s been 6 years and they&#39;ve identified sweet fuck all. This company is a scam and their &quot;AI&quot; is a fucking lie clearly. Other regular biotech companies have developed drugs and got them into trials in the last 6 years while this giant turd can&#39;t figure out a single fucking thing worth submitting. They should just pivot to being a bitcoin treasury company like the rest of the scam stocks already.

StockTwits Web

$ABCL @tutmose To add to this….it’s a very special type of credit card.  It is composed of more than 200k micro petri dishes. Each petri dish holds one cell and each cell is tracked using computers and analyzed using AI. Each cell emits natural antibodies in response to a pathogen. You can then discover which antibody does the best job out of all the antibodies that are produced in the more than 200k micro petri dishes. It makes discovering antibodies much more effective than the typical process. Abcellera is using this tech and their expertise to find effective antibodies that target known pathways in unique ways. Allowing for better safety, easier dosing and potentially much better efficacy. 

DYOR

StockTwits for iOS

AbCellera Biologics Inc

 Why consider buying ABCL?  Thanks to their AI, this company is able to identify a drug faster than almost anyone.  During COVID they discovered Bamlanivimab for Eli Lilly in just 11 days.  They screened 5 million cells and identified 500 unique sequence.  The drug went from discovery to human clinical trials in just 3 months and was approved by the FDA in 8 months.  Such process usually takes 5-10 years. 
 
They use credit card chips to screen millions of B cells.  Their AI predicts which sequence is most developable to prevent failure during manufacturing.   
 
They have full backing of the Canadian government with several grants totaling about $295 million.  They have almost $1.3 billion in total assets and are debt free.  They started developing their own drugs and within 6 months we will hear something about their most important trial ABCL365 to help with hot flashes caused by menopause (VMS market) is estimated at $17 billion/yr and will grow to $21 billion by 2030.

@tutmose You are missing out a big piece of context. During COVID drugs were brought forward under Emergency Use Authorization, which compresses 10 years of traditional clinical trials into a matter of months. So while Abcellera did discover Bam and Beb quickly, it&#39;s actually the FDA EMA review and approval process which made the biggest difference to the timeline.  
Now Abcellera are bringing forward their own pipeline in normal non-pandemic times, you can see the rate of progress is much slower, on the scale of several years until any FDA approval.

 You are missing out a big piece of context. During COVID drugs were brought forward under Emergency Use Authorization, which compresses 10 years of traditional clinical trials into a matter of months. So while Abcellera did discover Bam and Beb quickly, it's actually the FDA EMA review and approval process which made the biggest difference to the timeline.  
Now Abcellera are bringing forward their own pipeline in normal non-pandemic times, you can see the rate of progress is much slower, on the scale of several years until any FDA approval.